TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23548852

Group type: EXPERIMENTAL
Intervention: Multidisciplinary stress treatment programme (9 sessions over 3 months, including mindfulness-based stress reduction course for 2 hours a week over 8 weeks)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Multidisciplinary stress treatment programme
Number of subjects: 198

Group type: COMPARATOR
Intervention: Treatment-as-usual control group (12 consultations with a psychologist)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 198
Study: 21617185

Group type: EXPERIMENTAL
Intervention: Metreleptin administration for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 19538810

Group type: EXPERIMENTAL
Intervention: Cosmopolitan meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Animal-oriented meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Convenience meal
Number of subjects: 12
Study: 16717323

Group type: EXPERIMENTAL
Intervention: Paravertebral TENS (50 mA, 15 Hz, continuously)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 41
Study: 14566003

Group type: EXPERIMENTAL
Intervention: E5564, 3.5 mg/h x 72 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E5564, 3 mg/h x 4 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E5564, 0.5 mg/h x 4 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E5564, 252 mg after 72-h infusion
Number of subjects: 0
Study: 11561386

Group type: EXPERIMENTAL
Intervention: Focusing attention on a single limb
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Focusing attention on both limbs
Number of subjects: 52

Group type: COMPARATOR
Intervention: No-knowledge of results (KR) retention test
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Self-selected attentional strategy
Number of subjects: 52
Study: 9692702

Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxycillin + Clarithromycin (OAC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate + Amoxycillin + Clarithromycin (RbAC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: OAC (intention-to-treat)
Number of subjects: 81

Group type: COMPARATOR
Intervention: RbAC (intention-to-treat)
Number of subjects: 81
Study: 7524256

Group type: EXPERIMENTAL
Intervention: Haemodilution (H) with Hct decreased to 30% using hydroxyethyl starch 200/05
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study: 2893190

Group type: EXPERIMENTAL
Intervention: Short-course prednisone therapy (60 mg/m2 per 24 h until proteinuria disappeared for 3 days, then 40 mg/m2 per 48 h until complete remission)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard prednisone therapy (60 mg/m2 per 24 h for 4 weeks, then 40 mg/m2 per 48 h for 4 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Short-course prednisone therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard prednisone therapy
Number of subjects: 61
Study: 31064359

Group type: EXPERIMENTAL
Intervention: HMW-HA + UC
Number of subjects: 156

Group type: COMPARATOR
Intervention: UC
Number of subjects: 156
Study: 28185318

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcineurin Inhibitor (CNI)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 26603745

Group type: EXPERIMENTAL
Intervention: Self-management of blood pressure (self-monitoring with self-titration of antihypertensive medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25091790

Group type: EXPERIMENTAL
Intervention: De-escalation of empirical antimicrobial treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Continuation of empirical antimicrobial treatment
Number of subjects: 116
Study: 21761505

Group type: EXPERIMENTAL
Intervention: Cingulo-opercular Set Maintenance ICN activation during working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right Frontoparietal Control ICN activation during working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left Frontoparietal Control ICN activation during working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Default Mode ICN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual ICN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Set Maintenance, Frontoparietal Control, and Dorsal Attention ICNs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left Frontoparietal Control network activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left Frontoparietal Control and Dorsal Attention networks activation
Number of subjects: 0
Study: 19842003

Group type: EXPERIMENTAL
Intervention: Patient activation (measured by scores)
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Bilingual status and excellent health
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 1067
Study: 17223921

Group type: EXPERIMENTAL
Intervention: Suspicious PSA levels
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Suspicious DRE findings
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: PSA level and PSA velocity
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: High-grade prostatic intraepithelial neoplasia
Number of subjects: 2736
Study: 16036495

Group type: COMPARATOR
Intervention: Mail intervention (MIG)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Telephone intervention (TIG)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 636
Study: 12588695

Group type: EXPERIMENTAL
Intervention: High folate and high vitamin B-12 intake
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: High folate and high vitamin B-6 intake
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: High folate and low alcohol intake
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake
Number of subjects: 721

Group type: COMPARATOR
Intervention: Folate, methionine, vitamins B-6 and B-12 intake
Number of subjects: 721
Study: 9472888

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Serious medical complications
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Serious medical complications (after death discounted)
Number of subjects: 279
Study: 7625517

Group type: EXPERIMENTAL
Intervention: Demonstration condition (children living with mothers)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard community condition (children placed with caretaker)
Number of subjects: 53
Study: 2776869

Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline from a Turbuhaler inhaled as fast as possible (mean peak inspiratory flow rate = 53 l.min-1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Simple inhalation technique with terbutaline Turbuhaler
Number of subjects: 14
Study: 735294

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous Propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous Metoprolol
Number of subjects: 19
Study: 31083176

Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment for 6 weeks
Number of subjects: 193
Study: 27576099

Group type: EXPERIMENTAL
Intervention: Phone conversation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HelpLightning app
Number of subjects: 39

Group type: COMPARATOR
Intervention: User manual
Number of subjects: 39
Study: 26132298

Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Medical Advice (MA)
Number of subjects: 674
Study: 23780457

Group type: EXPERIMENTAL
Intervention: MMR booster vaccination
Number of subjects: 137

Group type: COMPARATOR
Intervention: No vaccination (control group)
Number of subjects: 137
Study: 21331970

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study: 19783397

Group type: EXPERIMENTAL
Intervention: BCTS-S inhalation of 5 mg morphine HCl
Number of subjects: 10

Group type: COMPARATOR
Intervention: BCTS-MC inhalation of 5 mg morphine HCl
Number of subjects: 10
Study: 16507343

Group type: EXPERIMENTAL
Intervention: Cognitive/behavioral group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study: 14985217

Group type: EXPERIMENTAL
Intervention: heptaglutamyl folic acid (323 nmol/d)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: monoglutamyl folic acid (262 nmol/d)
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: heptaglutamyl folic acid
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: heptaglutamyl folic acid and monoglutamyl folic acid
Number of subjects: 180
Study: 11376301

Group type: EXPERIMENTAL
Intervention: 40 mg/d pravastatin
Number of subjects: 2884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2884
Study: 9210854

Group type: EXPERIMENTAL
Intervention: Underhand grip with dowel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overhand grip with dowel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dowel with awkwardness ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dumbbell with same procedure as dowel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall analysis of end-state comfort effect
Number of subjects: 0
Study: 7971538

Group type: EXPERIMENTAL
Intervention: Life-style modification program (5 weekly 90-min sessions on modifying eating and exercise patterns)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Life-style modification program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 3528451

Group type: EXPERIMENTAL
Intervention: Pressure-controlled probing (50 g vertical force)
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Manual probing (uncontrolled pressure)
Number of subjects: 25000
Study: 30355107

Group type: EXPERIMENTAL
Intervention: Operator mTICI score
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Core lab mTICI score
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Operator and core lab mTICI scores
Number of subjects: 1130
Study: 27037161

Group type: EXPERIMENTAL
Intervention: I‐I‐Eye educational aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control aid
Number of subjects: 0
Study: 24967410

Group type: EXPERIMENTAL
Intervention: Noncardiac chest pain (NCCP) patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Female patients with NCCP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients with total TAS score more than 50
Number of subjects: 51
Study: 22736201

Group type: EXPERIMENTAL
Intervention: Qigong exercise intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 64
Study: 15998266

Group type: EXPERIMENTAL
Intervention: Zinc citrate/triclosan formulation with bromochlorophene
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zinc citrate/triclosan formulation without bromochlorophene
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control: proprietary fluoride toothpaste
Number of subjects: 24
Study: 11986508

Group type: EXPERIMENTAL
Intervention: Clomipramine + Psychodynamic Psychotherapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clomipramine alone
Number of subjects: 74
Study: 11360593

Group type: EXPERIMENTAL
Intervention: Diet control and insulin therapy (treated group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 98
Study: 8685072

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg day(-1))
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg day(-1))
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (TCA or neuroleptic treatment without SSRI)
Number of subjects: 29
Study: 2187230

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both iopamidol and iopromide
Number of subjects: 200
Study: 45064

Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin (250 micrograms/h, over 2 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study: 31618444

Group type: EXPERIMENTAL
Intervention: Guideline-concordant treatment
Number of subjects: 629
Study: 30478103

Group type: EXPERIMENTAL
Intervention: Online Climate Schools: Ecstasy and Emerging Drugs module (4 lessons over 4 weeks)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Full dose (completed all four lessons)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Incomplete dose (≤three lessons)
Number of subjects: 1126
Study: 27469482

Group type: COMPARATOR
Intervention: Standard of care (SOC) HF therapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: NT‐proBNP guided therapy (goal NT‐proBNP <1000 pg/mL)
Number of subjects: 151
Study: 25350223

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 256
Study: 24023318

Group type: EXPERIMENTAL
Intervention: CPT‐11/S‐1 (IRIS) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU)/l‐leucovorin (LV)/CPT‐11 (FOLFIRI) regimen
Number of subjects: 0
Study: 21940574

Group type: EXPERIMENTAL
Intervention: Virtual gastroscopy with MPR images
Number of subjects: 175

Group type: COMPARATOR
Intervention: Endoscopic ultrasound
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Virtual gastroscopy alone
Number of subjects: 175
Study: 18177441

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (K) during blood test stick (BT) procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard within-crib care (C) during blood test stick (BT) procedure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (K) during no blood test stick (W) procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard within-crib care (C) during no blood test stick (W) procedure
Number of subjects: 30
Study: 16276071

Group type: EXPERIMENTAL
Intervention: Mediterranean-like meal (45% fat, 1,000 Kcal, monounsaturated 61% of fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Western-like meal (saturated 57% of fat)
Number of subjects: 8
Study: 12975721

Group type: EXPERIMENTAL
Intervention: Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, dihydropyridine calcium antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple antihypertensive drugs
Number of subjects: 0
Study: 10731173

Group type: EXPERIMENTAL
Intervention: Supervised weight reduction programme including 8 week very low energy diet
Number of subjects: 38
Study: 9380472

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension 15 mg/kg
Number of subjects: 17
Study: 1390607

Group type: EXPERIMENTAL
Intervention: Iron supplementation combined with albendazole
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Albendazole only (Control)
Number of subjects: 2268
Study: 4020587

Group type: EXPERIMENTAL
Intervention: Alcohol education programs with a credible communicator and low fear appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol education programs
Number of subjects: 0
Study: 31904279

Group type: EXPERIMENTAL
Intervention: Average estimated tumor percentage
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Measured total tumor length
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Average calculated tumor percentage
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Greatest tumor length
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Greatest tumor percentage
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Average tumor percentage of all biopsies
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Calculated tumor length
Number of subjects: 1031
Study: 29332445

Group type: EXPERIMENTAL
Intervention: 70° stylet
Number of subjects: 162

Group type: COMPARATOR
Intervention: 90° stylet
Number of subjects: 162
Study: 27617373

Group type: EXPERIMENTAL
Intervention: Indirect resin composite onlays (IRC onlay)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stainless steel crowns (SSC)
Number of subjects: 50
Study: 24824648

Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose plus booster)
Number of subjects: 64
Study: 22285435

Group type: EXPERIMENTAL
Intervention: Remember (R) instructions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Forget (F) instructions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Neutral images
Number of subjects: 17

Group type: COMPARATOR
Intervention: Negative images
Number of subjects: 17
Study: 20624243

Group type: EXPERIMENTAL
Intervention: Active LENS intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham LENS intervention
Number of subjects: 34
Study: 18398528

Group type: EXPERIMENTAL
Intervention: Telephone based asthma management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 15992524

Group type: EXPERIMENTAL
Intervention: SGAs (risperidone and ziprasidone)
Number of subjects: 19

Group type: COMPARATOR
Intervention: FGA (haloperidol)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 19
Study: 12056293

Group type: EXPERIMENTAL
Intervention: 3 g/d sulfasalazine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 70
Study: 10692750

Group type: EXPERIMENTAL
Intervention: Cefaclor AF (750 mg b.d.)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (875/125 mg b.d.)
Number of subjects: 145
Study: 8726764

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard sedation
Number of subjects: 62
Study: 1768223

Group type: EXPERIMENTAL
Intervention: Follicular phase testing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Luteal phase testing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Natural menstrual cycle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose estrogen oral contraceptive pills
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: First test in follicular phase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: First test in luteal phase
Number of subjects: 24
Study: 6790206

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg, i.v. administration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline vehicle control
Number of subjects: 25
Study: 30902674

Group type: EXPERIMENTAL
Intervention: Elastic Resistance Training (ERT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 28342007

Group type: EXPERIMENTAL
Intervention: Phototherapy with LED 2.4 J/cm2 (wavelengths 625, 660, 850 nm) three times a week for 8 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group received phototherapy with broadband 580-900 nm and power density 0.72 J/cm2
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Phototherapy with LED
Number of subjects: 79
Study: 26121830

Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid therapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Postauricular steroid therapy
Number of subjects: 188
Study: 23126551

Group type: EXPERIMENTAL
Intervention: Emotional writing condition
Number of subjects: 748

Group type: COMPARATOR
Intervention: Non-emotional writing condition
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Repressors
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Defensive high-anxious individuals
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Low-anxious individuals
Number of subjects: 748
Study: 21338816

Group type: EXPERIMENTAL
Intervention: Skim milk powder diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Soybean concentrate diet
Number of subjects: 10
Study: 19805701

Group type: EXPERIMENTAL
Intervention: Oral naltrexone, 50 mg/d for 6 months (plus placebo implants)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Naltrexone implant, single dose of 2.3 g (plus placebo tablets)
Number of subjects: 70
Study: 17598625

Group type: EXPERIMENTAL
Intervention: Exercise group (aerobic plus resistance training for 16 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 73
Study: 15199090

Group type: EXPERIMENTAL
Intervention: D2 + para-aortic nodal dissection
Number of subjects: 523

Group type: COMPARATOR
Intervention: D2 lymphadenectomy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Both groups (D2 and D2 + para-aortic)
Number of subjects: 523
Study: 11498313

Group type: EXPERIMENTAL
Intervention: cis‐atracurium
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rocuronium
Number of subjects: 39

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 39
Study: 9649989

Group type: EXPERIMENTAL
Intervention: droperidol 0.05 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: droperidol 0.10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: droperidol 0.15 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: droperidol 0.20 mg
Number of subjects: 80
Study: 7853676

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 20 mg/kg administered via intravenous bolus injection or 30‐minute intravenous drip infusion 3 times daily for 3‐11 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 20 mg/kg
Number of subjects: 13
Study: 2688077

Group type: EXPERIMENTAL
Intervention: Clinical assessment techniques for RA trials
Number of subjects: 0